gvoke pfs Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gvoke Pfs, and what generic alternatives are available?
Gvoke Pfs is a drug marketed by Xeris and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-two patent family members in fifteen countries.
The generic ingredient in GVOKE PFS is glucagon. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gvoke Pfs
A generic version of gvoke pfs was approved as glucagon by FRESENIUS KABI USA on May 8th, 2015.
Summary for gvoke pfs
International Patents: | 22 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Patent Applications: | 4 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for gvoke pfs |
What excipients (inactive ingredients) are in gvoke pfs? | gvoke pfs excipients list |
DailyMed Link: | gvoke pfs at DailyMed |
US Patents and Regulatory Information for gvoke pfs
gvoke pfs is protected by two US patents.
Patents protecting gvoke pfs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA
Methods for producing stable therapeutic formulations in aprotic polar solvents
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF SEVERE HYPOGLYCEMIA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for gvoke pfs
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Tetris Pharma B.V | Ogluo | glucagon | EMEA/H/C/005391 Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. |
Authorised | no | no | no | 2021-02-11 | |
Eli Lilly Nederland B.V. | Baqsimi | glucagon | EMEA/H/C/003848 Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. |
Authorised | no | no | no | 2019-12-16 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for gvoke pfs
See the table below for patents covering gvoke pfs around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 3352780 | ⤷ Try a Trial | |
Brazil | 112018005800 | métodos para produzir formulações terapêuticas estáveis em solventes apolares apróticos | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017053922 | ⤷ Try a Trial | |
Japan | 6835831 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |